A tiny implant tested in Boston is providing a groundbreaking treatment for macular telangiectasia, a rare eye disease, by slowing or stopping its progression.

A tiny implant tested in Boston is providing a groundbreaking treatment for macular telangiectasia, a rare eye disease, by slowing or stopping its progression.

Alcon has acquired Neurotech Pharmaceuticals and Encelto, its macular telangiectasia type 2 therapy, according to a press release. Alcon paid $550 million in the acquisition of Neurotech and could make contingent payments based on commercial milestones, according to the release. Encelto (revakinagene taroretcel-lwey) is an encapsulated cell therapy that received FDA approval for the treatment of macular telangiectasia (MacTel) type 2 in March 2025. It is the only FDA-approved treatment for MacTel type 2. Jim Mazzo, executive chairman at Neurotech, told Healio he was pleased with the acquisition.

Alcon has acquired Neurotech Pharmaceuticals and Encelto, its macular telangiectasia type 2 therapy, according to a press release. Alcon paid $550 million in the acquisition of Neurotech and could make contingent payments based on commercial milestones, according to the release. Encelto (revakinagene taroretcel-lwey) is an encapsulated cell therapy that received FDA approval for the treatment of macular telangiectasia (MacTel) type 2 in March 2025. It is the only FDA-approved treatment for MacTel type 2. Jim Mazzo, executive chairman at Neurotech, told Healio he was pleased with the acquisition.

How a Northeastern-trained accountant ended up leading one of ophthalmology

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study spon...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study spon...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study spon...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study spon...

Phase 3 clinical trial results from Scripps Research and its collaborators supported FDA approval of ENCELTO, the first cell-based treatment for the neurodegenerative retinal disease known as MacTel. ...

Para las personas con telangiectasia macular tipo 2 (MacTel), un trastorno retiniano poco frecuente que destruye gradualmente la visión central, no ha habido opciones de tratamiento aprobadas desde ha...

DelveInsight’s “Macular Telangiectasia – Pipeline Insight, 2025” highlights the increasing interest in vision-preserving interventions, with more than 4

Encelto is the first and only approved treatment for MacTel type 2.

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech Pharmaceuticals is on the verge of making its commercial debut. | The FDA last week ap...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study spon...

Purpose To describe the successful use of plasma rich in growth factors (PRGF-Endoret®) and internal limiting membrane peeling for full thickness macular hole i...

So, you’ve decided to liberate your Intel Mac.Good choice.Now the big question: Which Linux distro should you install? There are hundreds. Most of them claim...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study sponsored by Neurotech Pharmaceuticals and spearheaded by investigators at Scripps Research and the National Institutes of Health offers compelling evidence that vision loss can be slowed with a neuroprotective surgical implant.

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study sponsored by Neurotech Pharmaceuticals and spearheaded by investigators at Scripps Research and the National Institutes of Health (NIH) offers compelling evidence that vision loss can be slowed with a neuroprotective surgical implant.

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss. That changed on March 6, 2025, with the approval of ENCELTO (revakinagene taroretcel-lwey), a surgically implanted device designed to preserve sight in people with this condition.